VIEMED HEALTHCARE, INC. Earnings Per Share Disclosure
| Year Ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Numerator - basic and diluted: | ||||||||||||||||||||
Net income attributable to Viemed Healthcare, Inc. | $ | 14,934 | $ | 11,265 | $ | 10,243 | ||||||||||||||
| Denominator: | ||||||||||||||||||||
| Basic weighted average number of common shares | 38,895,228 | 38,754,893 | 38,354,071 | |||||||||||||||||
| Diluted weighted average number of shares | 40,823,823 | 40,805,085 | 40,378,922 | |||||||||||||||||
| Basic earnings per share | $ | 0.38 | $ | 0.29 | $ | 0.27 | ||||||||||||||
| Diluted earnings per share | $ | 0.37 | $ | 0.28 | $ | 0.25 | ||||||||||||||
| Denominator calculation from basic to diluted: | ||||||||||||||||||||
| Basic weighted average number of common shares | 38,895,228 | 38,754,893 | 38,354,071 | |||||||||||||||||
| Stock options and other dilutive securities | 1,928,595 | 2,050,192 | 2,024,851 | |||||||||||||||||
| Diluted weighted average number of shares | 40,823,823 | 40,805,085 | 40,378,922 | |||||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 4, 2026 | Showing above |
| 2024 | Mar 10, 2025 | |
| 2023 | Mar 6, 2024 | |
| 2022 | Mar 2, 2023 | |
| 2021 | Mar 7, 2022 | |
| 2020 | Mar 3, 2021 | |
| 2019 | Mar 4, 2020 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.